Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

This study tests whether adding blinatumomab — a drug that directs the immune system to attack leukemia cells — can eliminate early residual disease in children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) who still have trace amounts of cancer after initial treatment. **You may be eligible if...** - Your child is between 1 month and 18 years old - They have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) confirmed by bone marrow biopsy and immune testing - After initial treatment, residual leukemia cells (MRD) were still detectable at specific cutoff levels (depending on risk group) - The child or guardian is able to understand and sign informed consent **You may NOT be eligible if...** - The leukemia has a specific surface marker (sIgM+) or arose from chronic myeloid leukemia - The child has Down syndrome or significant genetic/organ abnormalities - There is active central nervous system involvement - There is a history of epilepsy or recent seizures - The child has a known immune deficiency Talk to your doctor to see if this trial is right for you.